JP2023542093A5 - - Google Patents

Info

Publication number
JP2023542093A5
JP2023542093A5 JP2023515686A JP2023515686A JP2023542093A5 JP 2023542093 A5 JP2023542093 A5 JP 2023542093A5 JP 2023515686 A JP2023515686 A JP 2023515686A JP 2023515686 A JP2023515686 A JP 2023515686A JP 2023542093 A5 JP2023542093 A5 JP 2023542093A5
Authority
JP
Japan
Prior art keywords
cancer
inhibitor
pharmaceutical composition
composition according
immune checkpoint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542093A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/116498 external-priority patent/WO2022052874A1/zh
Publication of JP2023542093A publication Critical patent/JP2023542093A/ja
Publication of JP2023542093A5 publication Critical patent/JP2023542093A5/ja
Pending legal-status Critical Current

Links

JP2023515686A 2020-09-09 2021-09-03 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用 Pending JP2023542093A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010939961 2020-09-09
CN202010939961.4 2020-09-09
PCT/CN2021/116498 WO2022052874A1 (zh) 2020-09-09 2021-09-03 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用

Publications (2)

Publication Number Publication Date
JP2023542093A JP2023542093A (ja) 2023-10-05
JP2023542093A5 true JP2023542093A5 (https=) 2024-09-06

Family

ID=80632631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515686A Pending JP2023542093A (ja) 2020-09-09 2021-09-03 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用

Country Status (7)

Country Link
US (1) US20230321074A1 (https=)
EP (1) EP4212160A4 (https=)
JP (1) JP2023542093A (https=)
KR (1) KR20230066401A (https=)
CN (2) CN114224889B (https=)
TW (1) TW202214243A (https=)
WO (1) WO2022052874A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117597124A (zh) * 2021-07-08 2024-02-23 深圳微芯生物科技股份有限公司 西奥罗尼及其联合用药治疗乳腺癌的用途
WO2023160647A1 (zh) * 2022-02-24 2023-08-31 康方药业有限公司 包含抗ctla4-抗pd-1双特异性抗体和西奥罗尼的药物组合
WO2023193705A1 (zh) * 2022-04-07 2023-10-12 深圳微芯生物科技股份有限公司 西奥罗尼在抗胰腺癌中的用途
CN115177620A (zh) * 2022-07-18 2022-10-14 厦门大学附属第一医院 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用
CN119451679A (zh) * 2022-08-24 2025-02-14 应世生物科技(南京)有限公司 Fak抑制剂及微管抑制剂的药物组合及用途
WO2024055179A1 (zh) * 2022-09-14 2024-03-21 同济大学苏州研究院 Pd-1抗体药物继发耐药免疫抑制靶点及应用
CN115845052B (zh) * 2022-12-28 2023-12-29 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗结肠癌中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211901B2 (en) * 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
EP3079699A4 (en) 2013-12-11 2017-07-19 Glaxosmithkline LLC Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
PL3102605T3 (pl) 2014-02-04 2019-06-28 Pfizer Inc. Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN107868044B (zh) * 2016-09-27 2020-10-16 深圳微芯生物科技股份有限公司 一种非溶剂化晶体及其制备方法与应用
TWI764943B (zh) 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
CN106963948A (zh) 2017-05-12 2017-07-21 顾艳宏 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用
TW201902514A (zh) * 2017-06-05 2019-01-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途
WO2019096194A1 (zh) * 2017-11-16 2019-05-23 江苏恒瑞医药股份有限公司 Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
CN109893654B (zh) * 2017-12-11 2021-07-27 江苏恒瑞医药股份有限公司 Vegfr抑制剂治疗肿瘤的方法
KR102831159B1 (ko) * 2018-04-16 2025-07-07 온퀄리티 파마슈티컬스 차이나 리미티드 암 치료의 부작용을 예방하거나 치료하기 위한 방법
CN114681455A (zh) * 2018-08-17 2022-07-01 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途
CN109908143B (zh) * 2018-12-18 2021-11-19 厦门大学附属第一医院 西奥罗尼在制备治疗急性髓系白血病药物的新用途
CN112741905A (zh) * 2019-10-30 2021-05-04 江苏恒瑞医药股份有限公司 Vegfr抑制剂与抗pd-1抗体联合在制备治疗妊娠滋养细胞肿瘤的药物中的用途
WO2023160647A1 (zh) * 2022-02-24 2023-08-31 康方药业有限公司 包含抗ctla4-抗pd-1双特异性抗体和西奥罗尼的药物组合

Similar Documents

Publication Publication Date Title
JP2023542093A5 (https=)
JP2014527042A5 (https=)
HRP20202065T1 (hr) Kristalni oblik inhibitora mdm2
FI3986890T3 (fi) Bentsisoksatsolisulfonamidijohdannaisia
RU2015154275A (ru) Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf
JP2011126896A5 (https=)
JP2015520753A5 (https=)
HRP20231163T1 (hr) Prolijekovi glutaminskih analoga
HRP20100166T1 (hr) Postupak za pripremu 2-aminotiazol-5-aromatičnih karboksamida kao inhibitora kinaze
HRP20150771T1 (hr) Spoj za inhibiciju notch signalnog puta
JP2020536066A5 (https=)
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
RU2016108667A (ru) Комбинированная терапия для лечения рака
HRP20160014T1 (hr) Derivati 1-((5-heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamida kao inhibitori fosfatidilinozitol 3-kinaze (pi3k), koji su korisni u lijeäśenju proliferativnih bolesti
RU2010142390A (ru) Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения
JP2021534158A5 (https=)
JP2015536964A5 (https=)
JP2017526662A5 (https=)
JP2015536986A5 (https=)
RU2019142694A (ru) Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний
JP2016522202A5 (https=)
JP2021502415A5 (https=)
JP2024503235A5 (https=)
Pogorzelska et al. Novel 2-(2-alkylthiobenzenesulfonyl)-3-(phenylprop-2-ynylideneamino) guanidine derivatives as potent anticancer agents–Synthesis, molecular structure, QSAR studies and metabolic stability
JP2024515809A5 (https=)